Phase 2 RCT: Durvalumab plus Olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma.

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU) – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary from the author on Twitter

Results from Durva+/-Olaparib in 1L platinum ineligible mUC published in JCO. No benefit in ITT, but prolonged PFS in HRRm patients. Worthy of further investigation. Tough trial to do, made possible by great international team. @MSKCancerCenter @JCO_ASCO https://t.co/9hQNYoR5OE pic.twitter.com/bz1wTAXp7K

— Jonathan Rosenberg MD (@DrRosenbergMSK) June 24, 2022